Nagalingeswaran Ahilasamy, Kumar Rajendran Dinesh
Ahilasamy ENT Centre, Chennai, Tamil Nadu 600 042 India.
2Department of ENT and Head-Neck Surgery, Rajarajeswari Medical College and Hospital, Bengaluru, Karnataka 560 074 India.
Indian J Otolaryngol Head Neck Surg. 2020 Mar;72(1):133-139. doi: 10.1007/s12070-019-01772-1. Epub 2019 Dec 2.
Allergic rhinitis is a common disorder that affects several patients annually and the hallmark symptoms are nasal obstruction, rhinorrhea and sneezing which significantly impacts the quality of life. Many surgical options exist for the treatment of allergic rhinitis which is directed primarily addressing the nasal obstructive component. The purpose of this review article is to highlight newer surgical options in the management of patients with nasal allergy. Surgical modalities such as endoscopic resection of the posterior nasal nerve and senior author's own mini inferior turbinoplasty tunnelling technique for patients with nasal allergy is described here. Most of the literature has focused on medical management for patients with allergic rhinitis. Endoscopic Posterior Nasal neurectomy combined with mini inferior turbinoplasty has good overall significant improvement in nasal allergy symptom scores by 60-80%. Although no single modality has evolved as the gold standard for the surgical management of allergic rhinitis. The main stay of surgical intervention targets the inferior turbinate and posterior nasal nerve which is the parasympathetic supply to the nose causing rhinorrhea. This combined technique provides consistent, robust results with long-term relief of nasal symptoms due to allergic and vasomotor rhinitis without additional risk of complication.
过敏性鼻炎是一种常见疾病，每年影响众多患者，其标志性症状为鼻塞、流涕和打喷嚏，这些症状会显著影响生活质量。治疗过敏性鼻炎有多种手术选择，主要针对鼻阻塞成分。这篇综述文章的目的是强调鼻过敏患者管理中的新手术选择。本文描述了诸如鼻后神经内镜切除术以及资深作者自己为鼻过敏患者采用的迷你下鼻甲成形术隧道技术等手术方式。大多数文献都聚焦于过敏性鼻炎患者的药物治疗。鼻后神经内镜切除术联合迷你下鼻甲成形术能使鼻过敏症状评分总体显著改善60% - 80%。尽管尚未有一种单一术式成为过敏性鼻炎手术治疗的金标准。手术干预的主要目标是下鼻甲和鼻后神经，鼻后神经是导致流涕的鼻子副交感神经供应。这种联合技术能提供持续、可靠的效果，长期缓解过敏性和血管运动性鼻炎引起的鼻部症状，且无额外并发症风险。
